Dexamethasone and N-acetylcysteine (NAC)

ApprovedSmall molecule

Dexamethasone and N-acetylcysteine (NAC) is one of 19 small molecule programs targeting Poisoning. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PoisoningActive, not recruiting

PoisoningApproved

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Poisoning

#DrugCompanyPhaseTrials

Zofran

Novartis

Approved

1 2

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

1 3

Nimotop

AAzurity Pharmaceuticals

Phase 3

1 4

Osmitrol

BB. Braun Medical Inc.

Phase 3

1 5

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

1 6

Esmeron

FFresenius Kabi Oncology Ltd.

Phase 3

1 7

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 8

Sodium Hypochlorite

AAya Sabry Mohamed Mohamed

Approved

1 9

Atropine Sulfate

CCloudbreak Therapeutics, LLC

Phase 3

1 10

Atropen

FFresenius Kabi Oncology Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalRecruiting

Poisoning

NCT06811675

Clinical

Trials by Indication[1]

Poisoning1 trial

The Efficacy of Dexamethasone in Combination With N-acetylcysteine in Preventing Neurocognitive Sequelae Due to Carbon Monoxide Poisoning

Recruiting·—·Phase 4·NCT06811675·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dexamethasone and N-acetylcysteine (NAC). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dexamethasone and N-acetylcysteine (NAC) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dexamethasone and N-acetylcysteine (NAC). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — China Medical University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CChina Medical University Hospital

Dexamethasone and N-acetylcysteine (NAC)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Poisoning1 trial

References

Drug Info

Quick Facts

Related News